MGH Study: Varenicline Boosts Young Adults’ E-Cigarette Quit Rates by 50%

Apr.24
MGH Study: Varenicline Boosts Young Adults’ E-Cigarette Quit Rates by 50%
A study by Massachusetts General Hospital found that the oral smoking cessation drug varenicline significantly improves e-cigarette quit rates among young people aged 16 to 25. In a 12-week trial, 50% of participants in the varenicline group successfully quit vaping, compared to just 14% in the placebo group. After six months, 28% of those in the treatment group remained vape-free.

Key Points:

·A study conducted by Massachusetts General Hospital in the United States has shown that varenicline can significantly increase the success rate of e-cigarette cessation among individuals aged 16-25, marking the first randomized controlled trial to validate the effectiveness of this medication for young people. 

·The varenicline group had a quit rate of 50% at the end of the month, significantly higher than the placebo group's 14%; maintenance rates at 6 months were 28% vs 7%, respectively. 

·Researchers are urging doctors to actively inquire about e-cigarette use history and consider medication intervention when there is a need for cessation. 

·The prevalence of e-cigarette use among individuals aged 18-25 is as high as 24%, with illegally flavored products widely available and compliant products scarce. Experts have stated that this study fills a treatment gap and provides a medication pathway for interventions for e-cigarette addiction. 


According to a report by Statnews on April 23, Massachusetts General Hospital's latest research shows that the oral smoking cessation medication varenicline significantly increases the success rate of e-cigarette cessation among individuals aged 16 to 25. The study was published on April 23, 2025, in the Journal of the American Medical Association, marking the first trial of smoking cessation medication for e-cigarettes specifically targeting young people.

 

In a 12-week randomized controlled trial, a research team tracked 254 participants. The results showed that among those who received varenicline treatment, 50% successfully remained e-cigarette free in the last month, compared to only 14% in the placebo group. Six months later, the percentages of participants still maintaining abstinence were 28% in the varenicline group and 7% in the placebo group.

 

The research lead, Eden Evins, Director of the Addiction Medicine Center at Massachusetts General Hospital, pointed out that most doctors do not typically consider medication treatment as the first option when treating teenage e-cigarette use issues. Clinicians should proactively ask patients if they use e-cigarettes, if they experience withdrawal symptoms or cravings, and if so, should consider using varenicline for intervention.

 

Varenicline, marketed under the brand name "Chantix," was first approved by the United States Food and Drug Administration (FDA) in 2006. Its mechanism of action involves blocking nicotine's activation of dopamine in the brain, thereby reducing withdrawal symptoms and cravings. Common side effects include nausea and sleep disturbances.

 

Despite a decrease in e-cigarette usage among teenagers since the Juul craze, data from 2024 shows that 7.8% of high school students still used e-cigarettes in the past 30 days, with a high of 42% of high school e-cigarette users using them frequently or daily. The usage rate among 18 to 25-year-olds is even higher at 24%. Currently, the FDA has only authorized 34 e-cigarette brands for sale, but a large number of illegal products with fruit and candy flavors are still widely available through channels such as convenience stores and gas stations.

 

The study also found that simple behavior interventions have limited effectiveness. In the experiment, all participants received weekly behavior counseling for 12 weeks and were recommended to join the text support program "This is Quitting" operated by the non-profit organization Truth Initiative. The results showed that the combined effect of behavioral interventions with medication therapy was significantly better than behavioral interventions alone.

 

In order to ensure medication adherence, the research team requires participants to upload two medication videos each day and provides a $1 subsidy for each upload. The success of participants in quitting e-cigarettes is verified through the detection of cotinine, a nicotine metabolite, in their saliva. It is important to note that this study did not include individuals who smoke and use e-cigarettes simultaneously, so the results may not be applicable to this group.

 

Benjamin Toll, a professor at the Medical University of South Carolina and an expert in tobacco control not involved in the study, praised the research for its rigorous design and execution. He stated that "there are currently very few medication intervention options available for treating e-cigarette addiction, and this study provides a breakthrough for the industry.

 

Stanford University addiction research expert Judith Prochaska added that despite the limited sample size, the research results are of practical significance, and the side effects are manageable, with an overall low quit rate. She emphasized that the youth population lacks effective smoking cessation pathways, with the market flooded with high-nicotine, enticingly flavored products, making them more prone to addiction.

 

Thor pointed out that there are currently more than 10 generic versions of Venikaran available on the market, with an average monthly cost of around $100 without insurance. However, at his clinic, the cost is reduced to $20 per month due to insurance subsidies.

 

He added: "As researchers and clinical workers, we urgently need to develop practical and effective new intervention tools to help the public quit various addictive products including e-cigarettes, nicotine pouches, and marijuana.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Nicotine Company Chill Brands Posts £164,000 Half-Year Revenue, Shuts U.S. Subsidiary to Focus on Distribution
UK Nicotine Company Chill Brands Posts £164,000 Half-Year Revenue, Shuts U.S. Subsidiary to Focus on Distribution
Chill Brands H1 revenue fell 90% to $210,000, with a $3.1M operating loss tied to governance issues and one-off legal costs. The company exited the U.S., regained chill.com in Dec 2024, launched its Chill Connect platform, and raised £1M ($1.35M) via convertible debt in Apr 2025.
Jul.14 by 2FIRSTS.ai
Product | VOZOL Launches Two New E-Cigarettes with 40,000 Puffs and Four-Level Adjustable Output
Product | VOZOL Launches Two New E-Cigarettes with 40,000 Puffs and Four-Level Adjustable Output
VOZOL has launched two new e-cigarette models, VISTA 40K and STAR 40K, on its official website following their debut at the 2025 Dubai Expo. Featuring 40,000 puffs, a 1000mAh battery, “quantified” flavor descriptions, display screens, and S.i.L.C. Tech dual mesh coils, the devices are now available on UK distributor websites VapeSourcing and Vape Cave.
Jul.10
Imperial Brands Releases Study: Adult Smokers Reduced Cigarette Consumption After Using blu E-Cigarettes, with Flavours Playing a Key Role in Switching
Imperial Brands Releases Study: Adult Smokers Reduced Cigarette Consumption After Using blu E-Cigarettes, with Flavours Playing a Key Role in Switching
Two new studies from Imperial Brands show that adult smokers significantly reduced their cigarette use after switching to blu vapes, with flavors playing a key role.
Jun.17
RELX Technology Q1 2025 Financial Report: Revenue Rises 46.5% YoY to $110 Million, Slips 0.6% from Previous Quarter
RELX Technology Q1 2025 Financial Report: Revenue Rises 46.5% YoY to $110 Million, Slips 0.6% from Previous Quarter
RELX Technology reported net revenue of RMB 810 million (US $110 million) for Q1 2025, down 0.6% quarter-over-quarter but up 46.5% year-over-year. On a non-GAAP basis, adjusted net profit for the quarter was RMB 250 million (US $34.6 million), a 0.2% decrease from the previous quarter and a 21.0% increase from a year earlier.
May.16 by 2FIRSTS.ai
Australian Police Probe Illegal Vaping Network, Freeze $680,000 in Assets
Australian Police Probe Illegal Vaping Network, Freeze $680,000 in Assets
Australia’s AFP, in “Operation Smoke Storm,” froze over AUD 1 million ($680,000) tied to illegal vape sales. Online-branded e-cigarettes and transaction records were seized; funds may support community crime prevention.
Jul.14 by 2FIRSTS.ai
Insufficient Heating: Pain Point of Susceptor-Embedded HNB Smoking Article and Solutions thereof
Insufficient Heating: Pain Point of Susceptor-Embedded HNB Smoking Article and Solutions thereof
This article, contributed by patent attorney Ren Yongli to 2Firsts, analyzes the structural pain points of PMI's Terea sticks in electromagnetic heating and reviews technical solutions proposed by various industry players, including BAT, Shenzhen-based companies, and PMI’s own improvement strategies.
May.30